| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
|
N Engl J Med
|
2005
|
28.99
|
|
2
|
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
|
N Engl J Med
|
2006
|
10.89
|
|
3
|
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
|
Arch Gen Psychiatry
|
2007
|
5.64
|
|
4
|
Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.
|
Schizophr Res
|
2005
|
5.31
|
|
5
|
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
|
Am J Psychiatry
|
2006
|
4.12
|
|
6
|
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
|
Am J Psychiatry
|
2006
|
3.72
|
|
7
|
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.
|
Am J Psychiatry
|
2008
|
3.48
|
|
8
|
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.
|
Am J Psychiatry
|
2006
|
3.12
|
|
9
|
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
|
Am J Psychiatry
|
2007
|
2.75
|
|
10
|
Baseline neurocognitive deficits in the CATIE schizophrenia trial.
|
Neuropsychopharmacology
|
2006
|
2.70
|
|
11
|
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
|
Am J Psychiatry
|
2007
|
2.68
|
|
12
|
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline.
|
Schizophr Res
|
2006
|
2.60
|
|
13
|
Effectiveness of switching antipsychotic medications.
|
Am J Psychiatry
|
2006
|
2.38
|
|
14
|
Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial.
|
Biol Psychiatry
|
2005
|
2.24
|
|
15
|
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study.
|
Schizophr Res
|
2008
|
1.97
|
|
16
|
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1.
|
Schizophr Res
|
2008
|
1.95
|
|
17
|
Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study.
|
Biol Psychiatry
|
2005
|
1.90
|
|
18
|
Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease.
|
Arch Gen Psychiatry
|
2007
|
1.73
|
|
19
|
What CATIE found: results from the schizophrenia trial.
|
Psychiatr Serv
|
2008
|
1.55
|
|
20
|
Psychosocial outcomes following long-term, double-blind treatment of chronic depression with sertraline vs placebo.
|
Arch Gen Psychiatry
|
2002
|
1.55
|
|
21
|
Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia.
|
J Clin Psychiatry
|
2010
|
1.49
|
|
22
|
A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression.
|
Biol Psychiatry
|
2005
|
1.48
|
|
23
|
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.
|
Schizophr Res
|
2008
|
1.37
|
|
24
|
Extrapyramidal side-effects of antipsychotics in a randomised trial.
|
Br J Psychiatry
|
2008
|
1.37
|
|
25
|
The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome.
|
Schizophr Res
|
2005
|
1.28
|
|
26
|
Results of phase 3 of the CATIE schizophrenia trial.
|
Schizophr Res
|
2008
|
1.23
|
|
27
|
Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.
|
Schizophr Res
|
2005
|
1.20
|
|
28
|
The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial.
|
Schizophr Res
|
2009
|
1.04
|
|
29
|
The impact of obesity on health care costs among persons with schizophrenia.
|
Gen Hosp Psychiatry
|
2008
|
1.02
|
|
30
|
Comparison of serum, EDTA plasma and P100 plasma for luminex-based biomarker multiplex assays in patients with chronic obstructive pulmonary disease in the SPIROMICS study.
|
J Transl Med
|
2014
|
0.93
|
|
31
|
Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study.
|
Biol Psychiatry
|
2009
|
0.87
|
|
32
|
The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.
|
Schizophr Res
|
2008
|
0.86
|
|
33
|
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.
|
J Clin Psychiatry
|
2010
|
0.82
|
|
34
|
Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial.
|
Schizophr Res
|
2009
|
0.82
|